Read by QxMD icon Read

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Stephen W Stein, Charles G Thiel
In 1956, Riker Laboratories, Inc., (now 3 M Drug Delivery Systems) introduced the first pressurized metered dose inhaler (MDI). In many respects, the introduction of the MDI marked the beginning of the modern pharmaceutical aerosol industry. The MDI was the first truly portable and convenient inhaler that effectively delivered drug to the lung and quickly gained widespread acceptance. Since 1956, the pharmaceutical aerosol industry has experienced dramatic growth. The signing of the Montreal Protocol in 1987 led to a surge in innovation that resulted in the diversification of inhaler technologies with significantly enhanced delivery efficiency, including modern MDIs, dry powder inhalers, and nebulizer systems...
October 17, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Per Bäckman, Ulrika Tehler, Bo Olsson
BACKGROUND: Exposure following oral inhalation depends on the deposition pattern of the inhaled aerosol, the extent and rate of oral and pulmonary absorption, as well as systemic distribution and clearance. For lipophilic inhaled compounds with low water solubility and high permeability, the extent and rate of pulmonary absorption can be assumed dependent on deposition pattern as well as dissolution rate. MATERIALS AND METHODS: A mechanistic model of airway deposition, mucociliary clearance, dissolution, absorption, and dissipation was applied to simulate systemic exposure of the novel selective glucocorticoid receptor modulator, AZD5423, when dosed to healthy volunteers using two different nebulizers and two different dry powder inhalers in combination with two different primary particle size distributions...
October 14, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Lia Jahedi, Sue R Downie, Bandana Saini, Hak-Kim Chan, Sinthia Bosnic-Anticevich
BACKGROUND: Correct inhaler technique can increase medication efficacy, reducing both dose and side effects. Patient preference for inhaler device has not been fully explored, and we hypothesized that if patients have a preference and can choose their inhaler, they might be more likely to use it correctly. Our aim was to determine the preferences, attitudes, and perceptions of patients with asthma toward their inhalers, and to evaluate whether any of these factors were related to inhalation technique...
September 27, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Ross H M Hatley, Jacob Parker, John N Pritchard, Dirk von Hollen
BACKGROUND: Pressurized metered-dose inhalers (pMDIs) should be shaken before use to prevent creaming or sedimentation of the drugs in solution; however, data published on this topic are limited, and it is rarely specified how soon after shaking the device should be actuated. Delays between shaking and firing the pMDI have previously been shown to cause significant inhomogeneity in delivered dose. We studied the effect of various shake-fire delays on the drug delivered from five commercially available pMDIs commonly prescribed for asthma and chronic obstructive pulmonary disease to assess the potential variability in delivered dose...
September 16, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Wallace B Wee, Scott Tavernini, Andrew R Martin, Israel Amirav, Carina Majaesic, Warren H Finlay
BACKGROUND: Pediatric tracheostomies are not uncommon and aerosols allow for targeted lung therapy. However, there is little literature that quantifies aerosol delivery through tracheostomies. Nebulizers are commonly used in delivering tobramycin, but there are drawbacks, for example, time burden. Dry powder inhalers (DPIs) can deliver higher payloads in less time. However, no data exist assessing DPIs with tracheostomies. OBJECTIVE: The study's aim was to quantify the amount of aerosolized tobramycin delivered to the lungs of in vitro tracheostomized spontaneously breathing pediatric models with the TOBI(®) Podhaler™ (Podhaler) and the PARI LC Plus(®) (LC Plus)...
August 26, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Clizia Cazzarolli, Chiara Tartali, Ugo Pradal
No abstract text is available yet for this article.
August 26, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Nicolas Roche, Gerhard Scheuch, John N Pritchard, Cornelia Nopitsch-Mai, Deepika A Lakhani, Bhawana Saluja, Janine Jamieson, Andrew Dundon, Roisin Wallace, Susan Holmes, David Cipolla, Myrna B Dolovich, Samir A Shah, Svetlana Lyapustina
This article reports on discussions at the 2015 workshop cosponsored by the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) and the International Society for Aerosols in Medicine (ISAM), entitled "Regulatory and Patient Considerations for Inhalation Device Design, Development and Use." Key topics addressed at the workshop and presented here include patient-focused device design for orally inhaled products (OIPs), instructions for use (IFU), human factors, regulatory considerations in the United States and Europe, development of generic inhalers, quality-by-design, and change management of OIP devices...
August 18, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Abubaker Alatrash, Edgar Matida
BACKGROUND: Particle size and velocity are two of the most significant factors that impact the deposition of pressurized metered-dose inhaler (pMDI) sprays in the mouth cavity. pMDIs are prominently used around the world in the treatment of patients suffering from a variety of lung diseases such as asthma and chronic obstructive pulmonary disease. Since their introduction in the field, and as a result of their effectiveness and simplicity of usage, pMDIs are considered to be the most widely prescribed medical aerosol delivery system...
August 9, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Jean-Bernard Michotte, Enrico Staderini, Deborah Le Pennec, Jonathan Dugernier, Rares Rusu, Jean Roeseler, Laurent Vecellio, Giuseppe Liistro, Grégory Reychler
UNLABELLED: Backround: Coupling nebulization with noninvasive ventilation (NIV) has been shown to be effective in patients with respiratory diseases. However, a breath-synchronized nebulization option that could potentially improve drug delivery by limiting drug loss during exhalation is currently not available on bilevel ventilators. The aim of this in vitro study was to compare aerosol delivery of amikacin with a vibrating mesh nebulizer coupled to a single-limb circuit bilevel ventilator, using conventional continuous (Conti-Neb) and experimental inspiratory synchronized (Inspi-Neb) nebulization modes...
August 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Alberto Papi, Adel H Mansur, Tetyana Pertseva, Kirsten Kaiser, Tammy McIver, Birgit Grothe, Sanjeeva Dissanayake
BACKGROUND: A primary goal of asthma management is the reduction of exacerbation risk. We assessed the occurrence of oral corticosteroid-requiring exacerbations (OCS exacerbations) with long-term fluticasone/formoterol therapy, and compared it with the occurrence of similar events reported with other inhaled corticosteroid/long acting β2-agonist (ICS/LABA) combinations. METHODS: The occurrence of OCS exacerbations was assessed in two open-label trials of fixed-dose fluticasone/formoterol administered for between 26 to 60 weeks in adults and adolescents with asthma...
August 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Michael Caniga, Antonio Cabal, Khamir Mehta, David S Ross, Malgorzata A Gil, Janice D Woodhouse, Joseph Eckman, John R Naber, Marissa K Callahan, Luciano Goncalves, Susan E Hill, Robbie L Mcleod, Fraser McIntosh, Mark C Freke, Sandra A G Visser, Neil Johnson, Michael Salmon, Milenko Cicmil
BACKGROUND: Understanding the relationship between dose, lung exposure, and drug efficacy continues to be a challenging aspect of inhaled drug development. An experimental inhalation platform was developed using mometasone furoate to link rodent lung exposure to its in vivo pharmacodynamic (PD) effects. METHODS: We assessed the effect of mometasone delivered directly to the lung in two different rodent PD models of lung inflammation. The data obtained were used to develop and evaluate a mathematical model to estimate drug dissolution, transport, distribution, and efficacy, following inhaled delivery in rodents and humans...
August 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Rashmi Mehta, Mickael Montembault, Francis Warren, Ashutosh Gupta, Noushin Brealey, Alison Moore
BACKGROUND: The Mini Spacer has been developed for use with Ventolin(®) metered dose inhalers (MDIs) to improve accessibility to affordable spacers in developing countries. To ensure patient safety is not compromised if the Mini Spacer is used off-label with fluticasone propionate (FP) or salmeterol/FP combination (SFC) MDIs (currently not recommended), this study compared the systemic exposure of FP and salmeterol following delivery of FP and SFC MDIs with the Mini Spacer and the Aerochamber Plus(®) spacer (Aerochamber)...
August 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Nicolas Roche, P N Richard Dekhuijzen
Pressurized metered-dose inhalers (pMDIs) are sometimes viewed as old-fashioned and as having been superseded by dry powder inhalers (DPIs). Here, we review the technological advances that characterize modern pMDIs, and consider how they can influence the effectiveness of drug delivery for patients with asthma and chronic obstructive pulmonary disease. Compared with old chlorofluorocarbon (CFC)-based inhalers, many hydrofluoroalkane (HFA)-driven pMDIs have more favorable plume characteristics such as a reduced velocity and a higher fine particle fraction; together, these advances have resulted in the development of pMDIs with reduced oropharyngeal deposition and increased lung deposition...
August 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Mariateresa Stigliani, Michele Dario Manniello, Olga Zegarra-Moran, Luis Galietta, Laura Minicucci, Rosaria Casciaro, Emilia Garofalo, Loredana Incarnato, Rita P Aquino, Pasquale Del Gaudio, Paola Russo
BACKGROUND: Cystic fibrosis (CF) is characterized by a thick, sticky mucus responsible for both airway obstruction and resistance to drug diffusion, reducing the effectiveness of drug delivery to the lung. Studies of drug-mucus interaction may be a crucial step in therapeutic management of CF. In the present research, the effect of a saline solution of sodium bicarbonate (100 mM) on sputum viscosity and the permeation properties of ketoprofen lysinate (Klys) from a previously developed dry powder inhaler were evaluated...
August 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Mieke Boon, Mark Jorissen, Martine Jaspers, Patrick Augustijns, François L Vermeulen, Marijke Proesmans, Kris De Boeck
INTRODUCTION: Nebulized drugs are used in the treatment of cystic fibrosis (CF) lung disease, asthma, and COPD, and increasingly also in other chronic lung diseases. Their use in CF is reasonably evidence based, but this is not so for use in other orphan diseases. Potential side effects often have not been studied. Therefore, we evaluated the influence of nebulized drugs on ciliary activity in an in vitro model. METHODS: We constructed an in vitro nebulization model to examine the effect of drugs on ciliary activity...
August 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Heino Stass, Johannes Nagelschmitz, Dominik Kappeler, Knut Sommerer, Claudius Kietzig, Boris Weimann
BACKGROUND: Ciprofloxacin dry powder for inhalation (Ciprofloxacin DPI) is in development as long-term intermittent therapy to reduce the frequency of acute exacerbations in noncystic fibrosis bronchiectasis (NCFB) patients with respiratory bacterial pathogens. There is no approved therapy in this indication. Reliable, reproducible lung deposition is a prerequisite for inhaled drugs. METHODS: In this phase I study, six patients with NCFB, six with chronic obstructive pulmonary disease (COPD), and 12 healthy volunteers (HVs), received one dose of (99m)Tc-Ciprofloxacin DPI 32...
July 22, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Yasha Liang, Hefang Hu, Cuijie Tian, Yi Lei, Chuntao Liu, Fengming Luo
PURPOSE: Many methods have been developed to evaluate dry powder inhalation techniques and their efficiency for disease control in asthma patients. However, it is difficult to apply these methods to clinical practice and research. In this study, we introduce a simple new method that can be applied to dry powder inhalation techniques to evaluate their efficiency in clinical practice. METHODS: Twenty volunteers were recruited to evaluate the reliability of this new method...
July 12, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Sylvia Verbanck, Ghader Ghorbaniasl, Martyn F Biddiscombe, Dusica Dragojlovic, Nathan Ricks, Chris Lacor, Bart Ilsen, Johan de Mey, Daniel Schuermans, S Richard Underwood, Peter J Barnes, Walter Vincken, Omar S Usmani
BACKGROUND: While it is generally accepted that inertial impaction will lead to particle loss as aerosol is being carried into the pulmonary airways, most predictive aerosol deposition models adopt the hypothesis that the inhaled particles that remain airborne will distribute according to the gas flow distribution between airways downstream. METHODS: Using a 3D printed cast of human airways, we quantified particle deposition and distribution and visualized their inhaled trajectory in the human lung...
June 23, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Susanna Esposito, Chiara Rosazza, Calogero Sathya Sciarrabba, Nicola Principi
Upper respiratory tract infections (URTIs), primarily acute rhinopharyngitis, tonsillitis, adenoiditis, and rhinosinusitis (RS), are major causes of morbidity in both children and adults of any age. In addition to the frequent occurrence of related medical problems and the associated socioeconomic costs, URTIs have a significant impact on the quality of life of patients and their families, and have placed an escalating financial burden on the global healthcare system. Most URTIs are caused by viruses and require only symptomatic treatment...
June 23, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Jonathan E Phillips, Lorena Renteria, Lisa Burns, Paul Harris, Ruoqi Peng, Carla M T Bauer, Dramane Laine, Christopher S Stevenson
BACKGROUND: In allergen-induced asthma, activated mast cells start the lung inflammatory process with degranulation, cytokine synthesis, and mediator release. Bruton's tyrosine kinase (Btk) activity is required for the mast cell activation during IgE-mediated secretion. METHODS: This study characterized a novel inhaled Btk inhibitor RN983 in vitro and in ovalbumin allergic mouse models of the early (EAR) and late (LAR) asthmatic response. RESULTS: RN983 potently, selectively, and reversibly inhibited the Btk enzyme...
June 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"